INTRODUCTION {#s1}
============

*NUTM1*-rearranged tumors represent a genetically defined group of clinically aggressive cancers characterized by recurrent chromosomal rearrangements involving the *NUTM1* gene ([@MCS003194DIOC13]). Most *NUTM1*-rearranged tumors present as locally invasive and disseminated poorly differentiated carcinoma containing focal areas of squamous differentiation, usually occurring along the midline axis, and have been classified as NUT midline carcinomas (NCs) ([@MCS003194DIOC13]; [@MCS003194DIOC3]; [@MCS003194DIOC6]). Given the rarity and overlapping histopathologic features with other disparate tumors, the incidence of NCs remains difficult to determine. Although NCs were originally thought to predominate in childhood, increasing reports document a wide distribution of ages through adulthood ([@MCS003194DIOC23]; [@MCS003194DIOC34]; [@MCS003194DIOC13]; [@MCS003194DIOC3]; [@MCS003194DIOC12]). Perhaps the most clinically relevant feature of NC is its association with poor survival due to lack of durable responses despite conventional multimodality therapies (surgery, chemotherapy, and radiotherapy). Overall survival rates of 20%--30% underscore the need for accurate and timely diagnosis of NC and complete surgical resection of tumor, which has been associated with improved outcomes ([@MCS003194DIOC11]; [@MCS003194DIOC3]; [@MCS003194DIOC6]). Currently, use of adjuvant chemoradiotherapy has shown very limited benefit ([@MCS003194DIOC3]; [@MCS003194DIOC6]).

The characteristic cytogenetic abnormality observed in NCs is the presence of a reciprocal chromosomal translocation involving the *NUTM1* gene on Chromosome 15q14 with variant partner genes, most commonly the BET family gene *BRD4* and less commonly *BRD3*, *NSD3*, *ZNF532*, *MXD1*, *CIC*, and *BCORL1* ([@MCS003194DIOC14], [@MCS003194DIOC15]; [@MCS003194DIOC1]; [@MCS003194DIOC9]; [@MCS003194DIOC31]). Within the early descriptions of NC, cases included rarer variants that occurred outside of the anatomic midline, presenting instead as extremity tumors, resulting in initial alternative diagnoses ranging from Ewing sarcoma, pancreatoblastoma, neuroblastoma, to acute leukemia ([@MCS003194DIOC32]; [@MCS003194DIOC12]). Hence, the term NUT midline carcinoma was changed to NUT carcinoma by the World Health Organization classification of tumors ([@MCS003194DIOC33]). In addition, rare cases of sarcomas demonstrating no epithelial differentiation have been reported ([@MCS003194DIOC9]), suggesting that a subset of pure mesenchymal *NUTM1*-rearranged tumors are distinct from NC.

The advent of next-generation sequencing platforms that enable the identification of therapeutically relevant and targetable mutations and their incorporation into clinical diagnostics and treatment planning have offered renewed insight into the biology and potential curative approaches to rare and incurable cancers. In alignment with the concept of harnessing tumor genetic profiling to inform therapies, we developed a prospective program for screening patients with high-risk solid tumors with the goal of identifying drug-targetable mutations. As a result of this screening effort, we identified two cases with a primary diagnosis of high-grade spindle cell sarcoma harboring novel *MGA--NUTM1* fusions. We describe the genetic and histologic characterization of this novel fusion and discuss the implications of this case on the pathologic classification of *NUTM1*-rearranged tumors.

CLINICAL PRESENTATIONS {#s2}
======================

Case 1 {#s2a}
------

A previously healthy male presented at 10 yr of age with a history of leg pain and an enlarging thigh mass. The tumor was composed of a monomorphic spindle cell neoplasm arranged in vague sweeping fascicles. The tumor was associated with a peculiar dense hyalinized stroma, resembling amianthoid fibers. The tumor showed an increased mitotic activity of \>10 MF/10 HFs, but necrosis was absent. The immunohistological profile was nonspecific, showing focal positivity for CD99, CD34, and BCL-2, rare desmin, and otherwise focal negativity for pan-cytokeratin, CK7, EMA, S-100, GFAP, and myogenin. Although the morphologic appearance suggested the possibility of a monophasic synovial sarcoma, FISH was negative for the *SS18* gene rearrangement. A histological diagnosis of high-grade spindle cell sarcoma, not otherwise specified (NOS), was rendered. Radiographic workup did not demonstrate the presence of metastatic disease. The patient underwent surgical resection of the tumor but was found to have positive margins following pathologic review of resected tissue. The patient subsequently received adjuvant intensity-modulated radiation therapy (IMRT) (5580 cGy) but was found to have local recurrence proximal to the previous RT field ∼1 yr later. The recurrent tumor was biopsied showing histology similar to the initial tumor. The patient received neoadjuvant chemotherapy (ifosfamide and doxorubicin) followed by surgical resection. Consolidation with IMRT (5580 cGy) and adjuvant chemotherapy (ifosfamide/etoposide and additional cycles of ifosfamide/doxorubicin) followed. The patient was free of disease for \>6½ yr when he presented with a second local recurrence. Radiographic imaging showed no evidence of metastatic disease, with tumor histopathologically reminiscent of the original tumor. The patient was enrolled on an NCI Phase I clinical trial utilizing autologous activated NK cells in combination with IL-15 and cyclophosphamide (NCT01875601) followed by radiation therapy. He had resection of residual tumor and has since remained disease-free for 11 yr following initial diagnosis.

Case 2 {#s2b}
------

A previously healthy female presented at 10 yr of age with a 1-mo history of intermittent bilateral frontal headaches, followed by sudden onset vomiting and altered mental status. The patient was brought to a local emergency room for clinical workup, revealing a left-sided anterior intracranial mass and associated signs of increased intracranial pressure. She underwent an emergent left frontal craniotomy and was found to have a dural-based tumor that was completely resected. Subsequent diagnostic workup showed no evidence of metastatic disease. Pathology demonstrated a spindle cell sarcoma arranged in long intersecting fascicles. The tumor cells showed an isomorphic cytology, with variable mitotic activity and Ki-67 staining positive in only 10%--20% of cells. A variable collagenous stroma was present, ranging from scant to extensive. The immunohistologic profile was nonspecific for a line of differentiation, showing focal positivity for desmin and CD99, but negative for other markers including CD34, pan-cytokeratin, EMA, GFAP, STAT6, S-100, MUC4, BCOR, MYOD1, and SATB2. FISH testing was negative for rearrangements of *EWSR1*, *FUS*, and *SS18*. Given these results, a diagnosis of high-grade spindle cell sarcoma, NOS was made. The patient underwent focal RT (5580 cGy) to the resection cavity and has since been alive and well, with no evidence of disease, 15 mo following her initial diagnosis.

RESULTS {#s3}
=======

Genomic Analysis {#s3a}
----------------

### Case 1 {#s3a1}

We performed whole-genome sequencing (WGS) of the patient\'s primary tumor and matched normal tissue to a mean haploid coverage of 92× and 49×, respectively ([Fig. 1](#MCS003194DIOF1){ref-type="fig"}A; [Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003194/-/DC1)). The tumor sample was diploid and had high tumor content (73%). Analysis of the WGS data identified a total of 1116 somatic alterations (846 single-nucleotide substitutions, 252 indels, and 18 rearrangements) indicating a relatively low mutation burden (2.9 × 10^−4^ subs/Mb). Assessment of the contribution of known mutation signatures from COSMIC (<http://grch37-cancer.sanger.ac.uk/cosmic/signatures>) in the mutation spectrum of the substitution data showed that a majority of mutations were assigned to S-1 (aging-related, clock-like), S-3 (associated with biallelic inactivation of BRCA1 and BRCA2), and S-8 (unknown etiology) ([@MCS003194DIOC2]; [@MCS003194DIOC10]). However, the tumor did not exhibit other genomic features indicative of BRCA1/BRCA2 deficiency---namely, an excess of microhomology-mediated deletions, short \<10-kilobases (kb), or long \>100-kb tandem duplications---precluding the possibility of a "BRCAness" phenotype ([@MCS003194DIOC7]).

![(*A*) Whole-genome analysis identifies a novel *MGA--NUTM1* fusion in Case 1. (*I*) Circos plot summarizing the whole-genome sequencing (WGS) data. The two *innermost* tracks depict the integer copy-number changes for the major (brown) and minor (dark pink) allele. The *outermost* track shows the intermutation distance for substitutions each plotted according to the type of nucleotide change. The *middle* track shows the genomic positions of the small insertions (green) and deletions (red) along the genome. Rearrangements are plotted as arcs inside the Circos plot. Genes affected by potential oncogenic changes are annotated. (*II*) Mutation signature analysis of the substitutions using Mutational Patterns. Only the signatures with the 10 highest exposures are shown. (*III*) Summary of the indel data also showing the contribution of repeat- or microhomology-mediated mechanisms among deletions. (*IV*) Summary of rearrangement data. (*V*) Statistical analysis of the corrected variant allele frequency of substitution by Bayesian Dirichlet process--based clustering. Empiric histogram of substitutions is shown in gray together with the density from clustering in pale green and the fitted distribution in dark pink. Potential oncogenic alterations are annotated. (*B*) Integrated copy-number/rearrangement plots showing the WGS-based absolute copy number (*y*-axis) across the indicated genomic region (*x*-axis). Rearrangements are depicted as lines perpendicular to the *x*-axis.](MCS003194Dio_F1){#MCS003194DIOF1}

Case 1 revealed only two somatic changes of potential functional impact: a clonal copy-number gain on Chromosome 15 from intron 2/7 of *NUTM1* (Chr 15:34,639,000) to intron 22/24 of *MGA* (Chr 15:42,057,000), and a subclonal frameshift deletion in *NF2* (p.H195fs\*12) ([Table 1](#MCS003194DIOTB1){ref-type="table"}). Rearrangement analysis of WGS data identified an unbalanced translocation within a few bases of the breakpoint in intron-22 of the *MGA* locus (Chr 5:122919228:+ → Chr 15:420571 93:−) and supported by 14 reads, but failed to identify any aberrant read groups in intron 2 of *NUTM1* ([Table 1](#MCS003194DIOTB1){ref-type="table"}; [Fig. 1](#MCS003194DIOF1){ref-type="fig"}B).

###### 

Molecular characteristics of the two patients with *MGA--NUTM1* fusion

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor Type   Patient ID   Chr   Location    Wild type   Mutant             Allele frequency in tumor   Coverage in tumor   Allele frequency in normal   Coverage in normal   Variant Type    Genes affected   HGVS DNA change                      HGVS protein change   Predicted effect   ClinVar ID     IHC        Allele origin   Clinical significance
  ------------ ------------ ----- ----------- ----------- ------------------ --------------------------- ------------------- ---------------------------- -------------------- --------------- ---------------- ------------------------------------ --------------------- ------------------ -------------- ---------- --------------- -----------------------
  HGSCS        Case 1       22    30051645    AGAG\       A                  0.13                        67                  0                            48                   Deletion        *NF2*            c.580_586del\                        p.H195fs\*12          Frameshift         SCV000804554   Unknown    Somatic         Pathogenic
                                              CACC                                                                                                                                                              GAGCACC                                                                                                                 

  HGSCS        Case 1       5     122919229   T           T\]15:42057194\]   0.09                        152                 0                            66                   Translocation   *MGA*,\          t(5;15)(q23.2;q15.1)\                MGA/NUTM1             Fusion             SCV000804552   Retained   Somatic         Pathogenic
                                                                                                                                                                                               *NUTM1*          (g.71436_104584)                                                                                                        

  HGSCS        Case 2       15    34638819    A           \[15:42055110\[A   0.13                        123                 0                            70                   Translocation   *MGA*,\          t(15;15)(q14;15q.1)(g.753_102500)    MGA/NUTM1             Fusion             SCV000804554   Retained   Somatic         Pathogenic
                                                                                                                                                                                               *NUTM1*                                                                                                                                  

  HGSCS        Case 2       15    42054977    T           \[15:34638819\[T   0.17                        114                 0                            71                   Translocation   *MGA*,\          t(15;15)(q14;15q.1)(g.1016_102367)   MGA/NUTM1             Fusion             SCV000804553   Retained   Somatic         Pathogenic
                                                                                                                                                                                               *NUTM1*                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Genomic coordinates, wild type, and mutant alleles are reported in GRCh37 and according to VCF specifications.

HGSCS, high-grade spindle cell sarcoma.

### Case 2 {#s3a2}

The tumor sample had high tumor content (77%), and WGS of the patient\'s primary tumor and matched normal tissue to a mean haploid coverage of 91× and 49× was performed ([Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003194/-/DC1)). Analysis of the WGS data identified a total of 1389 somatic alterations (1047 single-nucleotide substitutions, 302 indels, and 40 rearrangements) confirming a relatively low mutation burden (3.6 × 10^−4^ subs/Mb) in this tumor ([Fig. 2](#MCS003194DIOF2){ref-type="fig"}A). Assessment of the contribution of known mutation signatures from COSMIC shows a similar signature profile distribution to Case 1 ([Fig. 2](#MCS003194DIOF2){ref-type="fig"}A).

![(*A*) Whole-genome analysis identifies a novel *MGA--NUTM1* fusion in Case 2. (*I*) Circos plot summarizing the whole-genome sequencing (WGS) data. (*II*) Mutation signature analysis of the substitutions using Mutational Patterns. (*III*) Summary of the indel data also showing the contribution of repeat- or microhomology-mediated mechanisms among deletions. (*IV*) Summary of rearrangement data. (*V*) Statistical analysis of the corrected variant allele frequency of substitution by Bayesian Dirichlet process--based clustering. For details, see legend to [Figure 1](#MCS003194DIOF1){ref-type="fig"}. (*B*) Integrated copy-number/rearrangement plots showing the WGS-based absolute copy number (*y*-axis) across the indicated genomic region (*x*-axis). Rearrangements are depicted as lines perpendicular to the *x*-axis.](MCS003194Dio_F2){#MCS003194DIOF2}

After reviewing all genomic alterations of Case 2, the only somatic alteration of potential functional impact was the *MGA--NUTM1* fusion created by a complex structural variant including multiple rearrangement breakpoints between intron 2/7 of *NUTM1* and intron 22/24 of *MGA* ([Table 1](#MCS003194DIOTB1){ref-type="table"}; [Fig. 2](#MCS003194DIOF2){ref-type="fig"}B). The same rearrangements were associated with a clonal deletion indicating that the fusion gene is found in 100% of the tumor cells.

Fluorescence In Situ Hybridization (FISH) {#s3b}
-----------------------------------------

Dual-color break-apart probes for the *NUTM1* gene were applied to tumor tissue samples from Case 1 ([Fig. 3](#MCS003194DIOF3){ref-type="fig"}A). No tissue from Case 2 was available for FISH testing. Tissue from two different resections of Case 1 showed satisfactory FISH signals with minimal background. Tissue from initial diagnosis exhibited a complex break-apart signal pattern consistent with a rearrangement at the *NUTM1* locus. Interestingly 60% of tumor cells showed a doublet of the *NUTM1* 3′ probe (orange signal). The same abnormal signal pattern was observed in tissue obtained from the patient\'s second local recurrence, ranging from 60% to almost 100% in various tumor areas (data not shown). In both samples, gain of extra signals were observed in a small percentage of cells. The signal patterns observed in these two samples were indicative of a complex rearrangement involving the 3′ *NUTM1* locus and consistent with the WGS findings.

![(*A*) Case 1: Fluorescence in situ hybridization assay showing evidence of complex *NUTM1* rearrangements. The arrow indicates examples of abnormal doublet signals of the 3′ *NUTM1* locus (orange). (*B*) RNA-sequencing reads spanning the junction between MGA exon 22 and NUTM1 exon 3. (*C*) RNA-seq coverage of MGA and NUTM1 exons. (*D*) Schematic representation of MGA and NUTM1 protein domains and resulting MGA--NUTM1 fusion protein structure. (*E*) H&E staining of both cases showed a monomorphic spindle cell morphology arranged in fascicles with an associated collagenous stroma. Case 1 showed dense hyalinized material, the so-called "amianthoid fibers," resembling osteoid matrix deposition. Immunohistochemically Case 1 showed strong, diffuse nuclear reactivity for NUTM1, whereas Case 2 showed a multifocal weak staining pattern. Scale bars, 500 µM.](MCS003194Dio_F3){#MCS003194DIOF3}

RNA-Sequencing Analysis {#s3c}
-----------------------

Analysis of RNA-seq data for fusion genes unequivocally identified an in-frame chimeric transcript containing exons 1--22 of *MGA* (NM_001164273.1) and exons 3--8 of *NUTM1* (NM_175741.2) in both cases ([Fig. 3](#MCS003194DIOF3){ref-type="fig"}B). The fusion was detected independently by three different fusion caller algorithms with high read support in both cases. RNA-seq coverage of all *MGA* exons and all but the first two exons of *NUTM1* confirm that expression of the fusion is driven by the *MGA* promoter ([Fig. 3](#MCS003194DIOF3){ref-type="fig"}C). The predicted MGA--NUTM1 fusion protein (3708 amino acids) is composed of almost the entire MGA protein and maintains both DNA binding domains of MGA (the Max interacting bHLH leucine zipper domain \[bHLHLZ\] and the T-box domain), as well as NUTM1 domains normally included in other NUT fusion proteins ([Fig. 3](#MCS003194DIOF3){ref-type="fig"}D). Analysis of the protein coding sequence identified two nuclear localization signals (NLSs) suggesting the fusion protein should localize to the nucleus.

Immunohistochemical Analysis {#s3d}
----------------------------

To confirm and localize the expression of MGA--NUTM1, we performed immunohistochemical analysis for NUTM1. As shown in [Figure 3](#MCS003194DIOF3){ref-type="fig"}D, the Case 1 primary tumor showed a diffuse (100% positive nuclei) intense nuclear staining for NUTM1, confirming the expression of the fusion at the protein level. Positive staining for NUTM1 was also confirmed in Case 1 recurrence and metastatic samples ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003194/-/DC1)). The Case 2 primary tumor had diffuse (60% positive nuclei) but weaker staining. In the former sample the staining was less intense and diffusely distributed than typical NUT carcinoma cases. These results may be due to the sensitivity of the IHC assay, which was optimized to detect levels typical in the testes and NUT carcinoma samples ([@MCS003194DIOC19]).

[Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003194/-/DC1) summarizes the results of all assays performed on the various surgical specimens. Through multiple orthogonal assays, we confirmed the presence and expression of a novel *MGA--NUTM1* fusion gene in two cases of pediatric high-grade sarcoma.

DISCUSSION {#s4}
==========

We describe the genetic and histologic characterization of two cases of high-grade spindle cell sarcoma harboring a novel *MGA--NUTM1* fusion. Most prior descriptions of *NUTM1*-rearranged tumors represent poorly differentiated carcinomas with variable degrees of squamous differentiation ([@MCS003194DIOC13]). Rare cases of NC with mesenchymal differentiation have been reported, with one case having the appearance of a poorly differentiated carcinoma with squamoid differentiation along with a malignant mesenchymal (chondroid) component positive for the *BRD4--NUTM1* fusion ([@MCS003194DIOC8]). There appear to be a group of spindle cell sarcomas harboring NUTM1 rearrangement that are completely distinct from NCs. These tumors harbored *BCORL1--NUTM1* and *CIC--NUTM1* rearrangements ([@MCS003194DIOC9]; [@MCS003194DIOC25]; [@MCS003194DIOC35]). Likewise, the two cases presented here lack any evidence of epithelial differentiation and show a high-grade sarcoma phenotype with a monomorphic/primitive cytomorphology. Notably, the expression of MGA--NUTM1 fusion is driven by the *MGA* gene promoter. During mouse embryonic development, *MGA* expression profiles overlap with those of several T-box transcription factors, and although it is widely expressed throughout the mouse embryo, it reaches its highest levels of expression in the limbs, branchial arches, and tail, suggesting its involvement in the induction of mesoderm ([@MCS003194DIOC21]; [@MCS003194DIOC5]). Therefore, it is plausible that expression of *NUTM1*-rearranged fusions, in particular *MGA--NUTM1*, within a progenitor cell of either neural crest or mesenchymal origin can drive the malignant transformation into a high-grade sarcoma.

The overall survival outcomes for NC patients have historically been poor with only a small percentage of survivors despite aggressive multimodality treatment ([@MCS003194DIOC11]; [@MCS003194DIOC3]; [@MCS003194DIOC6]). However, our two described pediatric cases of *MGA--NUTM1* sarcomas are both alive without evidence of disease. Surgical resection and radiotherapy were utilized in three cases (two cases described in this report and one case described by [@MCS003194DIOC8]), and systemic cytotoxic chemotherapy, utilizing a regimen used in the treatment of soft tissue and bone sarcomas, was used in two cases. Case 2 did not incorporate systemic therapy highlighting the importance of local control, via complete surgical resection and radiotherapy, in the management of this subset of *NUTM1*-rearranged tumors. Although the sum cases of *NUTM1*-rearranged sarcomas remain small, the curative outcomes associated with these tumors following multimodality treatment bear a striking and clinically notable contrast to patients with more classical features of NCs. Therefore, it will be imperative to fully characterize tumors of ambiguous lineage for the presence of *NUTM1* gene rearrangements and tissue lineage markers in order to identify this unique subset of *NUTM1*-rearranged tumors with associated mesenchymal markers and institute prompt multimodality therapies to maximize the chances of long-term cure.

In summary, we describe two cases of *NUTM1*-rearranged tumors with a novel *MGA--NUTM1* fusion gene occurring within the context of a histologically defined high-grade spindle cell sarcoma and in the absence of epithelial differentiation. We propose that the limited series of patients described herein and reported represent a new and distinct subset of *NUTM1* fusion-positive sarcomas that may be associated with a favorable prognosis presuming prompt institution of multimodality therapy. Given the unclear prevalence of *NUTM1*-rearranged tumors, screening for the presence of *MGA--NUTM1* or alternative *NUTM1* gene fusions should be considered in the routine diagnostic evaluation of high-grade spindle cell tumors and tumors of small round blue cell histology.

METHODS {#s5}
=======

Nucleic Acid Extraction {#s5a}
-----------------------

### DNA Extraction {#s5a1}

DNA extraction was performed following the manufacturer\'s protocol using DNeasy Blood & Tissue kit (QIAGEN).

### RNA Extraction {#s5a2}

Tissues were homogenized in 1 mL TRIzol (Invitrogen) using TissueLyzer (QIAGEN) and RNA extraction was performed following the manufacturer\'s protocol.

DNA- and RNA-Sequencing Preparation {#s5b}
-----------------------------------

DNA-sequencing libraries were prepared using the KAPA Library preparation kit (Kapa Biosystems). This process includes shearing the DNA, repairing the ends of the fragments, adding an A-base to the 3′ ends, ligating Illumina adapters, and amplifying the DNA to prepare samples for sequencing. The DNA was sheared to an average base pair size of 450 bp using the Covaris LE220 instrument (Covaris) under default settings. Following shearing, the DNA end repair step uses T4 DNA polymerase and Klenow DNA polymerase to remove 3′ overhangs and fill in the 5′ overhangs. As the adapter ligation requires the presence of a 3′ A-base on the double-stranded DNA fragments, the adenylation step uses dATPs and Exo(−) Klenow to adenylate the DNA fragments. Illumina NEXTflex-96 DNA adapters (Bioo Scientific) are attached to the 3′ ends using DNA ligase followed by PCR enrichment. The final libraries are then assayed for quality using the Agilent 2100 Bioanalyzer using the DNA 1000 chip (Agilent Technologies). Final libraries that passed QC have a concentration of \>2 ng/µl and a library size of \>200 bp with average peak height of 400 bp or greater.

For RNA preparation, samples used Kapa\'s Stranded RNA-Seq Kit with RiboErase (HMR) combined with Agilent\'s SureSelectXT Target Enrichment Kit for Illumina Multiplex Sequencing. RNA samples are fragmented using heat and magnesium and converted into cDNA. A-tailing is performed to add dAMP to the 3′ ends of the dscDNA library fragments. dsDNA adapters with 3′-dTMP overhangs are ligated to the A-tailed library insert fragments. Library fragments carrying appropriate adapter sequences at both ends were amplified using high-fidelity, low-bias PCR. Samples were then hybridized with biotinylated RNA library baits and the targeted regions are selected using magnetic streptavidin beads before amplification. The library quality was confirmed on an Agilent 2100 Bioanalyzer using the Agilent High Sensitivity chip and the quantity was confirmed using Thermo Fisher\'s Qubit 4 Fluorometer with the dsDNA BR Assay kit (Thermo Fisher Scientific). Final libraries passed QC with a concentration of \>2 ng/µl and an average peak height of \>300 bp.

DNA and RNA Sequencing {#s5c}
----------------------

DNA sequencing was performed on the Illumina HiSeq X 2 × 150 bp run (Illumina). The final DNA library was diluted, denatured, and introduced into the lanes of the flow cell using the Illumina cBot 2 system according to the manufacturer\'s protocol. The libraries were loaded at a 2:1 tumor:normal ratio to reach coverage (average read depth) of 80× for the tumor sample and 40× for the normal sample. RNA libraries were sequenced on the Illumina HiSeq 2500 2 × 50 bp Rapid Run platform multiplexing a total of seven samples onto one flow cell giving a minimum of 40,000 reads per sample.

Whole-Genome Sequencing and RNA Sequencing {#s5d}
------------------------------------------

### Alignment {#s5d1}

Short-insert paired-end reads were aligned to the GRCh37 reference human genome with 1000 Genomes decoy contigs using BWA-MEM ([@MCS003194DIOC24]).

### Substitution {#s5d2}

Single base substitutions were called using CaVEMan (Cancer Variants through Expectation Maximisation) (<http://cancerit.github.io/CaVEMan/>). As described previously ([@MCS003194DIOC28]), the algorithm compares sequence data from each tumor sample to its own matched noncancerous sample and calculates a mutation probability at each genomic locus. Copy-number and cellularity information for CaVEMan were predicted with the Battenberg algorithm ([@MCS003194DIOC28]) using 1000 Genomes ([@MCS003194DIOC17]) loci within the WGS data. Additional filtering criteria are described in [Supplemental Materials and Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003194/-/DC1).

### Small Insertions and Deletions {#s5d3}

Small somatic insertions and deletions (indels) were identified using a modified version of Pindel (<https://github.com/cancerit/cgpPindel>) ([@MCS003194DIOC30]). Variant annotation was done in Ensembl v74 using VAGrENT ([@MCS003194DIOC26]). Additional filtering criteria are described in [Supplemental Materials and Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003194/-/DC1).

### Structural Rearrangements {#s5d4}

Structural rearrangements were detected by an in-house algorithm, BRASS (Breakpoints via assembly; <https://github.com/cancerit/BRASS>), which first groups discordant read pairs that span the same breakpoint and then uses Velvet de novo assembler performs local assembly within the vicinity to reconstruct and determine the exact position of the breakpoint to nucleotide precision ([@MCS003194DIOC36]).

### Copy-Number Changes {#s5d5}

Segmental copy-number information was derived for each sample using the Battenberg algorithm as previously described ([@MCS003194DIOC28]). Additional filtering criteria are described in [Supplemental Materials and Methods](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003194/-/DC1).

### Mutational Signature Analysis {#s5d6}

Mutational signature analysis of the substitutions were performed using the R package mutational-signatures ([@MCS003194DIOC16]). Small insertion/deletions were interrogated for the presence of either short tandem repeat or microhomology at the breakpoints as described previously ([@MCS003194DIOC29]). Complex indels were excluded from this analysis.

### Clonality Analysis {#s5d7}

For each mutation we calculated corrected VAF (aka cancer cell fraction) as previously described ([@MCS003194DIOC4]), using the mutant allele burden, tumor purity, and locus-specific copy number in the tumor and matched normal. Subclones were identified by clustering the cancer cell fraction with Dirichlet process--based clustering as described previously ([@MCS003194DIOC18]).

### Fusion Detection {#s5d8}

RNA-seq data was interrogated for potential fusion genes using three different fusion callers: FusionCatcher ([@MCS003194DIOC27]), SOAPFuse ([@MCS003194DIOC22]), and STAR-Fusion ([@MCS003194DIOC20]).

Immunohistochemistry {#s5e}
--------------------

Immunohistochemical analysis was performed as previously described ([@MCS003194DIOC19]) using 4-µm formalin-fixed paraffin-embedded (FFPE) tissue sections using antibody to NUT (Cell Signaling; clone C52B1; 1:200).

FISH Analysis {#s5f}
-------------

FFPE tissue sections of 4 µm thickness with tumor areas marked were used for FISH following standard protocols. Briefly, the tissue sections were de-paraffinized in CitriSolv solution (Fisher Scientific), followed by dehydration in 100% ethanol. After heating in 20% citrate buffer, the tissue sections were treated with pepsin (0.5 mg/ml in 0.1 N HCl) for 10--25 min at 40°C, followed by fixation in 10% formalin, and dehydration in a series of 70%, 85%, and 100% ethanol. The *NUTM1* dual color break-apart probes (ZytoVision) contain a 5′ probe of 590 kb, labeled in green, and the 3′ probe of 455 kb, labeled in orange. After applying the FISH probes to the tissue areas, both tissue and probes were co-denatured for 7 min at 94°C, and then incubated overnight at 37°C, followed by posthybridization washing in 2× SSC/0.3% NP-40 for 2 min at 77°C. Tissue sections were counterstained with DAPI. Signal analysis was performed in combination with morphology correlation, and at least 100 interphase cells within the marked tumor area were evaluated. A positive result is determined if \>10% of cells show a split or other abnormal signal pattern.

ADDITIONAL INFORMATION {#s6}
======================

Data Deposition and Access {#s6a}
--------------------------

The results of whole-genome sequencing have been deposited into EGA (<https://www.ebi.ack.uk/ega/home>) under accession number EGAS00001003341, and RNA-seq data has been made available in the Gene Expression Omnibus (GEO) database. The genomic variants were submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000804554, SCV000804552, and SCV000804553.

Ethics Statement {#s6b}
----------------

Informed and signed consent was obtained and archived for the research performed and publication of the results. The patients were enrolled onto the Memorial Sloan Kettering Cancer Center (MSKCC) targeted gene sequencing research study (Genomic profiling in cancer patients; NCT01775072) with approval from the MSKCC Institutional Review Board under protocol IRB\# 12-245.
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